International

U.S. FDA approves Novartis therapy for prostate cancer

(Reuters) -The U.S. Meals and Drug Administration accredited Novartis AG’s remedy for the remedy of sufferers with a sort of superior prostate most cancers that has unfold to different components of the physique, the drugmaker stated on Wednesday.

Novartis’ Pluvicto is a focused radioligand remedy for grownup sufferers who’ve already undergone different anticancer remedies.

The corporate purchased the remedy as a part of its $2.1 billion buy of most cancers drugmaker Endocyte in 2018.

Pluvicto is a precision remedy combining a concentrating on compound, or ligand, with a cancer-killing radioactive particle, Novartis stated.

The corporate stated it has submitted advertising and marketing authorization for Pluvicto to the European Medicines Company and different well being authorities.

Two late-stage research evaluating Pluvicto in earlier traces of remedy for metastatic prostate most cancers are underway, in accordance with Novartis.

(Reporting by Manojna Maddipatla in Bengaluru; Modifying by Shounak Dasgupta)



Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button